Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $357.66M.
ENTERPRISE VALUE (EV)
$357.66M
Editas Medicine, Inc.
Market Cap
$439.67M
Enterprise Value (EV)
$357.66M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Editas Medicine, Inc. (EDIT) | $439.67M | $357.66M |
| NeoGenomics, Inc. (NEO)vs › | $434.25M | $737.07M |
| NeuroPace, Inc. (NPCE)vs › | $442.61M | $500.00M |
| Assembly Biosciences, Inc. (ASMB)vs › | $444.90M | $414.96M |
| Capricor Therapeutics, Inc. (CAPR)vs › | $449.16M | $519.27M |
| Prothena Corporation plc (PRTA)vs › | $425.48M | $144.28M |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $454.18M | $449.23M |
| Ovid Therapeutics Inc. (OVID)vs › | $454.47M | $455.86M |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $417.95M | $527.16M |
| Neurogene Inc. (NGNE)vs › | $416.39M | $312.25M |
Market Cap
$439.67M
Total Debt
$64.64M
Cash
$146.65M
Enterprise Value
$357.66M
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
